Skip to main content
. 2018 Feb 26;9(21):15658–15672. doi: 10.18632/oncotarget.24585

Figure 6. Ribociclib decreases Hey1 and PEO1 ovarian cancer tumor xenograft growth in combination with cisplatin.

Figure 6

(A) Sample dosing schedule for Ribociclib-only maintenance therapy and various combinations of sequential and concurrent treatment with cisplatin and Ribociclib. (B) Tumor growth in platinum-sensitive PEO1 xenografts treated with the indicated combinations of cisplatin with or without concurrent Ribociclib treatment and with or without Ribociclib maintenance therapy. (C) Hey1 tumor xenograft growth when treated with (i) vehicle vs. Ribociclib, (ii) vehicle control vs. cisplatin followed by vehicle (Cisplatin > vehicle) vs. cisplatin followed by Ribociclib maintenance (Cisplatin > Ribociclib), or (iii) cisplatin concurrent with Ribociclib followed by Ribociclib maintenance (Cis + Ribociclib > Ribociclib) vs. cisplatin alone followed by Ribociclib maintenance (Cis > Ribociclib). (D) IHC analysis of (i) pRB and (ii) Ki67 in tumors from the indicated treatment groups, and (iii) quantification of pRB and Ki67 marker-positive cells in the in the indicated treatment groups. Five high power fields from three sections of three tumors in each group were scored. ***p < 0.001 relative to the control.